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Edited by Valdimir SkulachevAbstract We previously reported that hypertrophy of vascular
smooth muscle cells caused by prostaglandin (PG) F2a is medi-
ated by the induction of NOX1, a catalytic subunit of NADPH
oxidase that generates superoxide. The signal transduction path-
way(s) involved in this process, however, remained unresolved.
PGF2a enhanced the phosphorylation of the epidermal growth
factor (EGF) receptor, and a selective inhibitor of EGF receptor
kinase, tyrphostin AG1478, signiﬁcantly suppressed PGF2a-in-
duced NOX1 expression. AG1478 also blunted the PGF2a-in-
duced phosphorylation of extracellular signal-regulated protein
kinase (ERK)1/2 and Akt. Phosphoinositide 3 (PI3) kinase
inhibitors not only reduced PGF2a-induced NOX1 expression,
but also suppressed the phosphorylation of ATF-1, a transcrip-
tion factor previously shown to play a key role in the induction
of NOX1. Accordingly, the transactivation of the EGF receptor
and the activation of ERK1/2, PI3 kinase, and ATF-1 constitute
the signaling pathways involved in the upregulation of NOX1.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Reactive oxygen species (ROS), including superoxide ðO2 Þ
and hydrogen peroxide (H2O2), have been recognized to act
as intrinsic signaling molecules in cardiovascular tissues. It
has been shown that NADPH oxidases are the major source
of O2 in vascular cells and cardiac myocytes [1–3]. Recently,
several homologs of the catalytic subunit of the phagocyte
NADPH oxidase (gp91phox; NOX2) were found in vascular
smooth muscle cells (VSMC). Among them, NOX1 was
implicated in the pathogenesis of atherosclerosis, hyperten-
sion, and restenosis after angioplasty, since it mediates the
proliferation and hypertrophy of VSMC. Expression of the
NOX1 gene is induced by angiotensin II, platelet-derivedAbbreviations: PG, prostaglandin; EGF, epidermal growth factor;
ERK, extracellular signal-regulated protein kinase; MAPK, mitogen-
activated protein kinase; MEK, MAPK/ERK kinase; MMP, matrix
metalloproteinase; PI3, phosphoinositide 3
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doi:10.1016/j.febslet.2005.01.021growth factor (PDGF), phorbol ester, and fetal bovine ser-
um (FBS) [4,5]. We previously reported that prostaglandin
(PG) F2a, one of the primary prostanoids generated in the
vascular tissue, causes hypertrophy of VSMC by the induc-
tion of NOX1 and the subsequent increase in O2 generation
[6]. Recently, we found that ATF-1, a transcription factor of
the CREB/ATF family, is essential for the upregulation of
NOX1 by PGF2a, PDGF, and other factors, including phor-
bol ester and FBS [7].
PGF2a exerts its biological actions through binding to its
speciﬁc G-protein-coupled receptor, FP [8]. FP is coupled to
phospholipase C and elicits the mobilization of cytosolic
Ca2+. In VSMC isolated from rat aorta, the activation of
extracellular signal-regulated kinase (ERK) 2, c-Jun-N-termi-
nal kinase (JNK) 1, phosphoinositide 3 (PI3)-kinase, and p70
S6 kinase by PGF2a has been reported [9]. It is as yet un-
known, however, whether these protein kinases take part in
the upregulation of NOX1 that leads to the generation of the
signaling molecule, O2 . Here, we report that the upregulation
of NOX1 by PGF2a involves the transactivation of the EGF
receptor, and ensuing activation of its downstream ERK1/2
and PI3 kinase–ATF-1 pathways.2. Materials and methods
2.1. Materials
Tyrphostin AG1478 and Wortmannin were purchased from Sigma
(St. Louis, MO). PGF2a was acquired from Nacalai Tesque (Kyoto, Ja-
pan). Antibodies against EGF receptor or phosphorylated EGF recep-
tor were obtained from Santa Cruz Biotechnology (Santa Cruz, CA)
and Biosource International (Nivelles, Belgium), respectively. Antibod-
ies against ERK or phosphorylated ERK were purchased from New
England Biolabs (Beverly, MA). Antibodies against Akt or phosphor-
ylated Akt and horseradish peroxidase-linked anti-rabbit or anti-mouse
antibodies were purchased from Cell Signaling Technology (Beverly,
MA). PP2, GM6001, PD98059, SB203580, and SP600125 were pur-
chased from Merck (Tokyo, Japan). LY294002 was purchased from
Cayman Chemical (Ann Arbor, MI). [a-32P]dCTP and [a-32P]UTP
were obtained from ICN Biomedicals (Costa Mesa, CA).
2.2. Cell treatment and Northern blot analysis
The rat VSMC line A7r5 obtained from American Type Culture
Collection (Rockville, MD) was seeded in 10-cm dishes (1 · 106 cells/
dish) and cultured for 24 h in Dulbeccos modiﬁed Eagles medium
(DMEM) supplemented with 10% FBS. The cells were then cultured
for a further 48 h in DMEM containing 0.5% FBS. After pretreatment
with or without various inhibitors for 1 h, the cells were subsequently
incubated with 100 nM PGF2a for 24 h. Northern blot analysis was
performed as described previously [6]. Representative autoradiographs
of the three experiments are shown in ﬁgures.ation of European Biochemical Societies.
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A7r5 cells cultured in the absence of FBS for 48 h were pretreated
with various inhibitors for 1 h, incubated with 100 nM PGF2a, washed
twice with PBS, and then frozen with liquid nitrogen. The cells were
lysed in a buﬀer containing 1% Triton, 0.5% sodium deoxycholate,
10 mM Tris–HCl, 150 mM NaCl, 1 mM EDTA, 20 mM b-glycero-
phosphate, 1 mM Na3VO4, 1 mM sodium ﬂuoride, and 1 mM phenyl-
methylsulfonyl ﬂuoride. The lysate was centrifuged and the
supernatant was saved for analysis. The aliquots containing equal
amounts of protein (10 lg) were subjected to SDS–polyacrylamide
gel electrophoresis and transferred onto polyvinylidene diﬂuoride
membranes (Millipore, Bedford, MA). After hybridization with a pri-
mary antibody and horseradish-peroxidase-linked secondary antibody,
immunoreactive bands were detected using an ECL-Plus System
(Amersham Biosciences, Piscataway, NJ). For the detection of ATF-
1, nuclear extracts were prepared and Western blot analyses were per-
formed as described previously [7]. Representative results of the three
experiments are shown in ﬁgures.
2.4. Statistical analysis
Values were expressed as means ± S.E.M. Statistical analysis was
performed with Students t test. For multiple treatment groups, one-
way ANOVA followed by Bonferronis t test was applied.3. Results
3.1. PGF2a transactivates EGF receptor
The mitogenic eﬀects of angiotensin II are mediated through
AT1 receptor and subsequent transactivation of the EGF
receptor [10]. Similar to the AT1 receptor, the prostanoid FPFig. 1. Involvement of EGF receptor transactivation in PGF2a-induced NOX
by PGF2a. Growth-arrested A7r5 cells were incubated with 100 nM PGF2a
Western blot analyses. The phosphorylation status of the EGF receptor w
Suppression of PGF2a-induced NOX1 expression by tyrphostin AG1478. Gr
for 1 h and subsequently incubated with 100 nM PGF2a for 24 h. (C) Sup
Growth-arrested A7r5 cells were treated with 50 lM PP2 or 20 lM GM6001
graphs represent means ± S.E.M. of the expression levels of NOX1 normaliz
control; P < 0.05 vs. PGF2a-treated cells.receptor is among the Gq-protein-coupled receptors [8]. To
examine whether PGF2a transactivates the EGF receptor in
A7r5 cells, phosphorylation of the EGF receptor was analyzed
by Western blotting using a phospho-speciﬁc antibody. As
shown in Fig. 1A, a time-dependent increase in the phosphor-
ylation of the EGF receptor was demonstrated in the cells
stimulated with PGF2a. Increased phosphorylation of the
EGF receptor was clearly observed 0.5 min after stimulation
with PGF2a, and the level reached a maximum at 2 min.3.2. Inhibitors of EGF receptor kinase, Src, and matrix
metalloproteinase (MMP) suppress the induction of NOX1
mRNA by PGF2a
To examine whether the transactivation of the EGF receptor
is involved in NOX1 induction, A7r5 cells were stimulated
with PGF2a for 24 h in the presence or absence of tyrphostin
AG1478, a selective inhibitor of EGF receptor kinase. As
shown in Fig. 1B, tyrphostin AG1478 signiﬁcantly suppressed
the PGF2a-induced increase in NOX1 mRNA. Transactivation
of the EGF receptor by angiotensin II is mediated by the acti-
vation of tyrosine kinases Src and Pyk2, and the ADAM fam-
ily of MMPs, leading to the excision of heparin-binding EGF
[10]. Therefore, eﬀects of inhibitors of Src and MMPs were
investigated. As shown in Fig. 1C, a Src inhibitor PP2 and a
MMP inhibitor GM6001 suppressed the PGF2a-induced in-
crease in NOX1 mRNA. These results suggest that the activa-
tion of Src and MMPs is involved in the transactivation of the1 expression. (A) Time course of transactivation of the EGF receptor
for the indicated period and the cell lysates (10 lg) were subjected to
as analyzed with anti-phospho-speciﬁc EGF receptor antibody. (B)
owth-arrested A7r5 cells were treated with 10 lM tyrphostin AG1478
pression of PGF2a-induced NOX1 expression by PP2 and GM6001.
for 1 h and subsequently incubated with 100 nM PGF2a for 24 h. Bar
ed to those of GAPDH obtained from three experiments. *P < 0.05 vs.
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sion of the NOX1 gene.
3.3. PGF2a-induced activation of ERK1/2 is suppressed by an
EGF receptor kinase inhibitor
The angiotensin II-induced transactivation of the EGF
receptor leads to the activation of ERK [11,12]. We therefore
examined whether PGF2a activates ERK in A7r5 cells. As
shown in Fig. 2A, a time-dependent increase in the phosphor-
ylation of ERK1/2 was demonstrated in the cells stimulated
with PGF2a. Increased phosphorylation was clearly observed
2 min after stimulation and the level reached a maximum at
5 min. As shown in Fig. 2B, the phosphorylation of ERK1/2
was signiﬁcantly suppressed in the presence of tyrphostin
AG1478. These results suggest that the activation of ERK1/2
by PGF2a is mediated by the transactivation of the EGF recep-
tor in A7r5 cells.
3.4. MEK inhibitor suppresses the induction of NOX1 by PGF2a
PGF2a was found to activate multiple mitogen-activated
protein kinase (MAPK) cascades [9]. To examine whether
ERK and other MAPK are involved in NOX1 induction, ef-
fects of MAP kinase inhibitors were investigated. As shown
in Fig. 2C, a MAPK/ERK kinase (MEK) inhibitor,
PD98059, signiﬁcantly suppressed the PGF2a-induced increase
in NOX1 mRNA. On the other hand, neither SB203580 nor
SP600125, inhibitors of p38 and JNK, respectively, aﬀected
the induction of NOX1 mRNA by PGF2a. These results sug-Fig. 2. Involvement of ERK1/2 in PGF2a-induced NOX1 expression. (A) Tim
were incubated with 100 nM PGF2a for the indicated period and the cell lysa
PGF2a-induced phosphorylation of ERK1/2 by tyrphostin AG1487. Growt
AG1478 for 1 h, and then incubated with or without 100 nM PGF2a for 5
expression. Growth-arrested A7r5 cells were treated with 10 lM PD98059 (a
(a JNK inhibitor) for 1 h, and subsequently incubated with 100 nM PGF2agest that MEK–ERK is the major pathway in the MAPK cas-
cades involved in the upregulation of NOX1.3.5. PGF2a-induced activation of the PI3 kinase pathway is
blocked by an EGF receptor kinase inhibitor
It has been reported that the PI3 kinase/Akt pathway is also
activated by PDGF or angiotensin II to mediate the mitogen-
esis of VSMC [13,14]. We then examined whether PGF2a acti-
vates Akt, a substrate of PI3 kinase. As shown in Fig. 3A, a
time-dependent phosphorylation of Akt was observed in the
cells stimulated with PGF2a, reaching a maximum at 2 min.
To clarify whether this PI3 kinase/Akt pathway is placed
downstream of the EGF receptor, the eﬀect of tyrphostin
AG1478 was tested. As shown in Fig. 3B, the phosphorylation
of Akt was signiﬁcantly suppressed by the EGF receptor ki-
nase inhibitor. These results suggest that the activation of
the PI3 kinase pathway takes place downstream of the EGF
receptor.3.6. PI3 kinase inhibitors suppress the induction of NOX1 by
PGF2a
We next veriﬁed eﬀects of PI3 kinase inhibitors on PGF2a-
induced NOX1 expression. As shown in Fig. 3C, PI3 kinase
inhibitors Wortmannin and LY294002 almost completely
abolished the PGF2a-induced increase in NOX1 mRNA, indi-
cating the involvement of PI3 kinase in the PGF2a-induced in-
crease in NOX1 expression.e course of ERK1/2 activation by PGF2a. Growth-arrested A7r5 cells
tes (10 lg) were subjected to Western blot analyses. (B) Suppression of
h-arrested A7r5 cells were treated with or without 10 lM tyrphostin
min. (C) Eﬀects of MAP kinase inhibitors on PGF2a-induced NOX1
MEK inhibitor), 10 lM SB203580 (a p38 inhibitor) or 5 lM SP600125
for 24 h. *P < 0.05 vs. control; P < 0.05 vs. PGF2a-treated cells.
Fig. 3. Involvement of PI3 kinase in PGF2a-induced NOX1 expression. (A) Time course of Akt activation by PGF2a. Growth-arrested A7r5 cells
were incubated with 100 nM PGF2a for the indicated period and the cell lysates (10 lg) were subjected to Western blot analyses. (B) Suppression of
PGF2a-induced phosphorylation of Akt by tyrphostin AG1487. Growth-arrested A7r5 cells were treated with or without 10 lM tyrphostin AG1478
for 1 h and then incubated with or without 100 nM PGF2a for 2 min. (C) Suppression of PGF2a-induced NOX1 expression by PI3 kinase inhibitors.
Growth-arrested A7r5 cells were treated with 200 nMWortmannin or 25 lM LY294002 for 1 h, and subsequently incubated with 100 nM PGF2a for
24 h. (D) Suppression of PGF2a-induced phosphorylation of ATF-1 by PI3 kinase inhibitors. Growth-arrested A7r5 cells were pre-incubated with
200 nM Wortmannin or 25 lM LY294002 for 1 h and subsequently stimulated with 100 nM PGF2a for 10 min. *P < 0.05 vs. control;
P < 0.05 vs.
PGF2a-treated cells.
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PGF2a
We next examined which pathway is involved in the activa-
tion of ATF-1, a transcription factor of the CREB/ATF family
previously shown to mediate the upregulation of NOX1 [7].
Tyrphostin AG1478 suppressed phosphorylation of ATF-1 in-
duced by PGF2a (data not shown). PI3 kinase inhibitors mark-
edly suppressed phosphorylation of ATF-1 (Fig. 3D). On the
other hand, a MEK inhibitor, PD98059, did not aﬀect the
PGF2a-induced phosphorylation of ATF-1, even at a concen-
tration of 100 lM (data not shown). Accordingly, the activa-
tion of ATF-1 by PGF2a is mediated by PI3 kinase.4. Discussion
Based on the present ﬁndings, transactivation of the EGF
receptor by PGF2a and subsequent activation of ERK1/2,
PI3 kinase, and ATF-1 appears to constitute the signaling
pathways that lead to the upregulation of NOX1. The majorlines of evidence provided in this study are that: (1) PGF2a
enhanced the phosphorylation of the EGF receptor and a
selective inhibitor of EGF receptor kinase suppressed the
PGF2a-induced increase in NOX1 mRNA; (2) a Src inhibitor,
PP2, and a MMP inhibitor, GM6001, suppressed PGF2a-in-
duced NOX1 expression; (3) an inhibitor of EGF receptor ki-
nase blunted the PGF2a-induced phosphorylation of ERK1/2,
and a MEK inhibitor suppressed PGF2a-induced NOX1
expression; (4) an inhibitor of EGF receptor kinase abolished
the PGF2a-induced phosphorylation of Akt, a substrate of PI3
kinase; and (5) PI3 kinase inhibitors suppressed PGF2a-in-
duced NOX1 expression as well as the PGF2a-induced phos-
phorylation of ATF-1.
PGF2a exerts its biological actions through binding to its
speciﬁc G-protein-coupled receptor, FP [8]. FP is coupled to
phospholipase C and elicits the mobilization of cytosolic
Ca2+. Some of its eﬀects are, however, reported mediated
through the transactivation of the EGF receptor. Proliferation
of an endometrial adenocarcinoma cell line induced by PGF2a
was attributed to the transactivation of the EGF receptor and
subsequent activation of ERK1/2 [15]. In cultured TMOb oste-
C. Fan et al. / FEBS Letters 579 (2005) 1301–1305 1305oblasts, PGF2a activates ERK1/2 through the transactivation
of the EGF receptor to elicit the recruitment and activation
of osteoblasts [16]. Our present data clearly indicated that
the induction of NOX1 by PGF2a and ensuing hypertrophy
of VSMC [6] is also mediated through the transactivation of
the EGF receptor and activation of ERK1/2.
There is little information on signaling pathways involved
in the induction of NOX1, although various vasoactive fac-
tors, including angiotensin II, PDGF, and PGF2a, were re-
ported to induce NOX1 in VSMC [4–6]. We presently
demonstrated that the EGF receptor is transactivated by
PGF2a, and we also observed that PDGF elicits phosphory-
lation of the EGF receptor in A7r5 cells (data not shown).
The transactivation of the EGF receptor therefore seems
to be a common event involved in induction of NOX1 by
these factors. Recently, the upregulation of NOX1 by the
Ras oncogene in NRK cells was reported to be mediated
by the MEK–ERK pathway, and the increased ROS gener-
ation due to NOX1 was required for oncogenic cell transfor-
mation [17]. Our present ﬁndings in VSMC consequently
support the view that the EGF receptor and downstream
ERK1/2 may mediate the induction of NOX1 by a wide
range of stimuli in diﬀerent cell lineages.
We previously reported that ATF-1, a transcription factor
of the CREB/ATF family, is essential for the upregulation of
NOX1 by PGF2a, PDGF, and other factors, and the inhibi-
tion of the mitochondrial respiratory chain suppresses the
phosphorylation of ATF-1 [7]. However, the question as to
which signaling pathway(s) leads to the activation of ATF-1
was left unanswered. Here, we demonstrated that PI3 kinase
is the upstream module that activates ATF-1 and induces the
expression of the NOX1 gene. PI3 kinase inhibitors, but not
a MEK inhibitor, suppressed the PGF2a-induced phosphory-
lation of ATF-1. On the other hand, PGF2a-induced phos-
phorylation of ERK1/2 was not aﬀected by PI3 kinase
inhibitors, or by depletion of ATF-1 with RNAi (data not
shown). Thus, the PI3 kinase–ATF-1 pathway and the
MEK–ERK1/2 pathway, both downstream of the EGF
receptor, are independently activated to elicit induction of
NOX1. Considering the fact that NOX1-derived O2 is asso-
ciated with the proliferation and hypertrophy of VSMC, it
is reasonable that PI3 kinase and ERK1/2, both known to
mediate cell survival and growth, constitute the signal trans-
duction pathways that lead to the up-regulation of NOX1
gene expression.
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